

Sprint Bioscience presents preclinical data from the TREX1 program at AACR IO

Sprint Bioscience AB (publ) today announces that the company's TREX1 program will be presented at the conference AACR IO Discovery and Innovation in Cancer Immunology.

Sprint Bioscience will present results from the TREX1 program and will participate with a poster at the conference AACR IO Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy, which will be held in Los Angeles, California, from February 23 to 26, 2025.

The positive results from an in vivo proof-of-concept study show that treatment with the company's TREX1 inhibitors results in an improved immune response and inhibited tumor growth.

"Existing approved immunotherapies all have a different mechanism which makes this approach unique. When blocking TREX1 in tumors, the body's immune response is reactivated, resulting in inhibition of tumor growth. This represents a novel approach to amplifying the immune response and our data support the therapeutic hypothesis in this program. We are proud and excited to present the program to scientists and potential partners in the immuno-oncology field," said Martin Andersson, CSO at Sprint Bioscience.

Recent publications show that the function of the TREX1 protein in cancer cells inhibits the immune response. This, in combination with the company's data, confirms the hypothesis that TREX1 is an interesting new target for cancer therapy.

The poster "Inhibition of TREX1 increases type I interferon signaling and reduces tumor growth in vivo" is presented by Madhurendra Singh, PhD, Associate Principal Scientist, Sprint Bioscience.

AACR IO is a conference organized by the American Association for Cancer Research. It's a specialized conference with participants from companies and academic groups that focus on research and drug development to block cancer cells' ability to escape the immune response in the tumor. The conference covers everything from basic research to clinical trials, and also, a lot of previously unpublished information.

For further information, kindly contact:

Johan Emilsson, CEO, Sprint Bioscience
Tel: +46 (8) 411 44 55
Epost: johan.emilsson@sprintbioscience.com

About Sprint Bioscience AB (publ)

Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs are out-licensed to global pharmaceutical companies during the pre-clinical phase and the company has successfully entered into several license agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company's website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.

Attachments

[Sprint Bioscience presents preclinical data from the TREX1 program at AACR IO](#)